For high-intensity statin groups , evolocumab every @ weeks reduced LDL-C from a baseline mean of @ to @ mg/dL to an on-treatment mean of @ to @ mg/dL ; monthly evolocumab reduced LDL-C from a baseline mean of @ to @ mg/dL to an on-treatment mean of @ to @ mg/dL .